Indian J Pharm Sci. 2013 Jul;75(4):463-75. doi: 10.4103/0250-474X.119832.

Synthesis, SAR Study and Evaluation of Mannich and Schiff Bases of Pyrazol-5(4H)-one Moiety Containing 3-(Hydrazinyl)-2-phenylquinazolin-4(3H)-one.

Indian journal of pharmaceutical sciences

K K Sivakumar, A Rajasekharan, R Rao, B Narasimhan

PMID: 24302802 PMCID: PMC3831729 DOI: 10.4103/0250-474X.119832

Abstract

In the present investigation, a series of 12 Mannich bases (QP1-12) and 5 Schiff bases (QSP1-5) of pyrazol-5(4H)-one moiety containing 3-(hydrazinyl)-2-phenylquinazolin-4(3H)-one has been synthesized and characterized by physicochemical as well as spectral means. The synthesized Mannich and Schiff bases were screened for their preliminary antimicrobial activity against Gram-positive and Gram-negative bacterial as well as fungal strains by the determination of zone of inhibition. Mannich bases (QP1-12) were found to be more potent antibacterial agents against Gram-positive bacteria, whereas Schiff bases (QSP1-5) were more potent against Gram-negative bacteria and fungi. Minimum inhibitory concentration result demonstrated that Mannich base compound (QP7) having ortho -OH and para -COOH group showed some improvement in antibacterial activity (minimum inhibitory concentration of 48.88×10(-3) μM/ml) among the tested Gram-positive organisms and it also exhibit minimum inhibitory concentration of value of 12.22×10(-3) μM/ml for Klebsiella pneumoniae. The antitubercular activity of synthesized compounds against Mycobacterium tuberculosis (H37Rv) was determined using microplate alamar blue assay. Compound QP11 showed appreciable antitubercular activity (minimum inhibitory concentration of 6.49×10(-3) μM/ml) which was more active than the standard drugs, ethambutol (minimum inhibitory concentration of 7.60×10(-3) μM/ml) and ciprofloxacin (9.4×10(-3) μM/ml). Compounds QP11, QP9, QSP1, QSP2, and QSP5 have good selective index and may be selected as a lead compound for the development of novel antitubercular agents.

Keywords: Antimicrobial; antimycobacterium; cytotoxicity; pyrazolone; quinazolinones

References

1. Eur J Med Chem. 2009 Jul;44(7):3020-6 - PubMed
2. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4022-6 - PubMed
3. Eur J Med Chem. 2007 Sep;42(9):1234-8 - PubMed
4. Clin Microbiol Rev. 2006 Oct;19(4):658-85 - PubMed
5. Bioorg Med Chem. 2012 Jul 1;20(13):4103-8 - PubMed
6. J Antimicrob Chemother. 2001 Jul;48 Suppl 1:5-16 - PubMed
7. Bioorg Med Chem. 2007 Jan 1;15(1):484-94 - PubMed
8. Pharm Acta Helv. 1999 Dec;74(1):11-7 - PubMed
9. Bioorg Med Chem. 2006 May 1;14(9):3113-8 - PubMed
10. Biol Pharm Bull. 2003 Apr;26(4):557-9 - PubMed
11. Antimicrob Agents Chemother. 2001 Jul;45(7):1943-6 - PubMed
12. J Natl Cancer Inst. 1991 Jun 5;83(11):757-66 - PubMed
13. Bioorg Med Chem. 2010 Feb 15;18(4):1563-72 - PubMed
14. J Enzyme Inhib Med Chem. 2011 Oct;26(5):720-7 - PubMed
15. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1793-8 - PubMed
16. Bioorg Med Chem Lett. 2008 Feb 1;18(3):918-22 - PubMed
17. Eur J Med Chem. 2008 Mar;43(3):456-63 - PubMed
18. J Immunol Methods. 1983 Dec 16;65(1-2):55-63 - PubMed
19. Farmaco. 2002 Jul;57(7):583-7 - PubMed
20. Eur J Med Chem. 2009 Nov;44(11):4690-4 - PubMed
21. Antimicrob Agents Chemother. 1997 May;41(5):1004-9 - PubMed
22. Molecules. 2006 Jun 12;11(6):383-92 - PubMed
23. Molecules. 2007 Dec 27;12(12):2621-42 - PubMed
24. Clin Microbiol Rev. 2003 Jul;16(3):463-96 - PubMed
25. Eur J Med Chem. 2003 Jan;38(1):27-36 - PubMed
26. Eur J Med Chem. 2008 Oct;43(10):2122-9 - PubMed
27. Eur J Med Chem. 2010 Dec;45(12):6085-9 - PubMed

Publication Types

• Journal Article